PARKS DIAGNOSTICS - Key Persons
Ali is a highly skilled bioinformatician with four years of experience analysing multi-omic clinical datasets, with a special focus on proteomics, metabolomics and single cell data analysis. Ali's current focus is on multivariate analysis of next generation proteomics and clinical data.
Anniina is involved in validation of targets that may contribute to the pathology of Parkinson's disease. She is carrying out her PhD studies within the PARKS project.
Dani trained in mass spectrometry in Peter James's lab in Sweden. He joined the PARKS team in 2016 and together with James, he has established next-generation proteomics methods at PARKS. Dani works on mass spectrometry analysis methods and data analysis.
Job Titles:
- Project Leader, Neuroscience
- Project Leader, R & D
- Research Director at Turku Bioscience Centre
Dr. Coffey is Research Director at Turku Bioscience Centre where she leads the Protein Kinase Function in Brain group. Her career in neuroscience spans 30 years investigating the molecular basis of neurological disorders. She and her team have identified key mechanisms contributing to nerve cell death and anxiety-like behaviors. Her team identified that LRRK2, a key player in Parkinson's disease represses protein synthesis, leading to the initiation of PARKS.
Job Titles:
- Commercialization Coordinator
Dr. Hollos is a neuroscientist with expertise in coordination. He has worked in the Coffey laboratory since 2013. During this time he helped coordinate a 4.5 million EU project r'BIRTH ITN 2014-2017 involving 9 EU partners. He looks after marketing, legal aspects, business strategy, pitching for investors, pitching for customers.
Job Titles:
- Expert, Mass Spectrometry
Dr. James is a pioneer of proteomics-based mass spectrometry. His research has focused over the last 30 years on the development of diagnostic tests for cancer and mass spectrometry-based methods development. He has 7 world-wide patents based on methodological advances in mass spectrometry. Also, he has advised venture capital companies specializing in early-stage biotech such as 3i, Atlas Ventures, and Sofinnova. Prof. James is responsible for mass spectrometry-based technology development for PARKS.
Steve Diggle, CEO Vulpes Investment Management, Singapore; Jeremy Haigh, Consultant UK (former CEO of Proteome Sciences, former COO Amgen Europe); Kyriacos Mitrophanous, CSO, Oxford Biomedica, UK; Juha Rouru, Director of Neurodegenerative Diseases, Orion Corporation, Finland.
Job Titles:
- Expert, Movement Disorders
- Specialist
Dr. Kaasinen is a specialist in movement disorders. He diagnoses and treats patients with Parkinson's disease in South-west Finland. He specializes in the use of functional brain PET and SPECT neurotransmitter imaging for Parkinson's disease, other movement disorders, and behavioral addictions. He is involved in several projects that aim to improve the clinical value of brain dopamine transporter imaging for Parkinson's disease and atypical parkinsonian disorders. Dr. Kaasinen is the clinical advisor for PARKS.
Job Titles:
- Coordinator
- Patient and Regulatory Affairs
Dr. Fagerholm has considerable experience working with clinical trial data management, working in a hospital and contract research organization setting. Veronica is responsible for quality management at PARKS.
Ye is an experienced bioinformatician and mathematician with extensive knowledge gained during a period spanning >10 years in the US and Europe, in academia, and in the biotech sector. Ye has developed software pipelines for data analysis and signature recognition at PARKS.